Cardiac Dimensions, a Kirkland, Wash.-based leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, closed a $17.5m Series C financing.
All existing shareholders participated in the round including Aperture Venture Partners, Arboretum Ventures, Hostplus, Life Sciences Partners, Lumira Ventures, and M. H. Carnegie & Co.
The financing will be used to accelerate commercial sales of Cardiac Dimensions’ Carillon Mitral Contour System® in Europe and allow for expansion into other geographies such as Australia. Earlier this month, Australia’s Therapeutic Goods Administration approved the Carillon System for commercial use in FMR patients with mild to severe mitral regurgitation.
Led by Rick Wypych, Chief Executive Officer and President, Cardiac Dimensions develops innovative, minimally invasive treatments to address heart failure and related cardiovascular conditions. The company is advancing the Carillon System, which offers a simple right heart approach to transcatheter mitral valve repair designed to reshape the anatomy and function of the mitral apparatus from the coronary sinus.
The Carillon System, CE-marked (0344), has been implanted in over 1,200 patients in the U.S., Europe, Australia, Turkey and the Middle East. The Carillon System is currently being studied in The CARILLON Trial pivotal trial and limited to investigational use in the United States.